CoChat

Rationale for short course primaquine in Africa to interrupt malaria transmission

Eziefula, Alice C, Gosling, Roly, Hwang, Jimee, Hsiang, Michelle S, Bousema, Teun, von Seidlein, Lorenz, Drakeley, Chris · 2012 · Malaria Journal
Cited by 46

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria. The drug has scarcely been used in Africa because of concerns about its safety in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The evidence base for the use of primaquine as a transmission blocker is limited by a lack of comparable clinical and parasitological endpoints between trials. In March 2012, a group of experts met in London to discuss the existing evidence on the ability of primaquine to block malaria transmission, to define the roadblocks to the use of primaquine in Africa and to develop a roadmap to enable its rapid, safe and effective deployment. The output of this meeting is a strategic plan to optimize trial design to reach desired goals efficiently. The roadmap includes suggestions for a series of phase 1, 2, 3 and 4 studies to address specific hurdles to primaquine’s deployment. These include ex-vivo studies on efficacy, primaquine pharmacokinetics and pharmacodynamics and dose escalation studies for safety in high-risk groups. Phase 3 community trials are proposed, along with Phase 4 studies to evaluate safety, particularly in pregnancy, through pharmacovigilance in areas where primaquine is already deployed. In parallel, efforts need to be made to address issues in drug supply and regulation, to map G6PD deficiency and to support the evaluation of alternative gametocytocidal compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2875-11-360

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. World Health Organization: Guidelines for the treatment of malaria. 2011, WHO, Geneva, 2
  2. World Health Organization: World Malaria Report 2011. 2011, WHO, Geneva · DOI · Paper page
  3. Clyde DF: Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Bull World Health Organ. 1962, 27: 203-212.
  4. Abeyaratne KP, Halpe NL: Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. Ceylon Med J. 1968, 13: 134-138.
  5. Reeve PA, Toaliu H, Kaneko A, Hall JJ, Ganczakowski M: Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. J Trop Med Hyg. 1992, 95: 349-351.
  6. Khoo KK: The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol. 1981, 75: 591-595. · DOI
  7. Burgess RW, Bray RS: The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull World Health Organ. 1961, 24: 451-456.
  8. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R: Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012, 9: e1001165-10.1371/journal.pmed.1001165. · DOI · Paper page
  9. Perine PL, Michael MT: A preliminary survey for glucose-6-phosphate dehydrogenase deficiency and haemoglobin S in Ethiopia. Ethiop Med J. 1974, 12: 179-184.
  10. Mackerras MJ, Ercole QN: Some observations on the action of quinine, atebrin, and plasmoquine on Plasmodium vivax. Trans R Soc Trop Med Hyg. 1949, 42: 443-454. 10.1016/0035-9203(49)90050-4. · doi:10.1016/0035-9203(49)90050-4
  11. Mackerras MJ, Ercole QN: Observations on the action of quinine, atebrin and plasmoquine on the gametocytes of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1949, 42: 455-463. 10.1016/0035-9203(49)90051-6. · doi:10.1016/0035-9203(49)90051-6
  12. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006, 75: 402-415. · DOI · Paper page
  13. Chemotherapy of malaria and resistance to antimalarials: Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1973, 529: 1-121.
  14. Gunders AE: The effect of a single dose of pyrimethamine and primaquine in combination upon gametocytes and sporogony of Laverania falcipara (Plasmodium falciparum) in Liberia. Bull World Health Organ. 1961, 24: 650-653.
  15. Brewer GJ, Tarlov AR, Alving AS: Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity. Bull World Health Organ. 1960, 22: 633-640.
  16. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE: Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960, 22: 621-631.
  17. Hockwald RS, Arnold J, Clayman CB, Alving AS: Toxicity of primaquine in Negroes. J Am Med Assoc. 1952, 149: 1568-1570. 10.1001/jama.1952.72930340027010c. · doi:10.1001/jama.1952.72930340027010c
  18. Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL: Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis. 1995, 171: 1569-1575. 10.1093/infdis/171.6.1569. · doi:10.1093/infdis/171.6.1569
  19. Baird JK, Surjadjaja C: Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011, 27: 11-16. 10.1016/j.pt.2010.08.005. · DOI
  20. Hodgkinson R, Courtney KO, Haggerty M: Effect of intermittent administration of a combination of amodiaquin and primaquine (Camoprim) on the hematocrit of primaquine-sensitive and non-sensitive children. Am J Trop Med Hyg. 1961, 10: 128-134. · doi:10.4269/ajtmh.1961.10.128
  21. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD: Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ. 1968, 38: 625-632.
  22. Rieckmann KH, McNamara JV, Kass L, Powell RD: Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil Med. 1969, 134: 802-819. · doi:10.1093/milmed/134.9.802
  23. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T: Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One. 2007, 2: e1023-10.1371/journal.pone.0001023. · DOI · Paper page
  24. Shekalaghe SA, Ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T: Haemolysis after a single dose of primaquine co-administered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase (G6PD A- variant) deficient individuals in Tanzania. Antimicrob Agents Chemother. 2010, 54: 1762-1768. 10.1128/AAC.01135-09. · DOI
  25. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H, Li G: Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J. 2010, 9: 57-10.1186/1475-2875-9-57. · DOI
  26. von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, Coleman R, Jawara M, Lindsay SW, Drakeley C, De Martin S, Olliaro P, Bennett S, Schim Van Der Loeff M, Okunoye K, Targett GA, McAdam KP, Doherty JF, Greenwood BM, Pinder M: The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 2003, 97: 217-225. 10.1016/S0035-9203(03)90125-8. · DOI · Paper page
  27. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T: A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011, 10: 247-10.1186/1475-2875-10-247. · DOI
  28. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ: The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J (Engl). 1994, 107: 709-711.
  29. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, Bonnet S, Diallo M, Coulibaly M, Tchuinkam T, Mulder B, Targett G, Drakeley C, Sutherland C, Robert V, Doumbo O, Touré Y, Graves PM, Roeffen W, Sauerwein R, Birkett A, Locke E, Morin M, Wu Y, Churcher TS: Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One. 2012, 7: e42821-10.1371/journal.pone.0042821. · DOI · Paper page
  30. Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, Sauerwein RW: Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg. 2007, 76: 470-474. · DOI · Paper page
  31. Bousema T, Drakeley C: Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011, 24: 377-410. 10.1128/CMR.00051-10. · DOI · Paper page
  32. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani AC, Drakeley C: Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010, 9: 136-10.1186/1475-2875-9-136. · DOI · Paper page
  33. Mendez F, Munoz A, Plowe CV: Use of area under the curve to characterize transmission potential after antimalarial treatment. Am J Trop Med Hyg. 2006, 75: 640-644. · DOI
  34. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA: The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol. 2006, 22: 424-430. 10.1016/j.pt.2006.07.001. · DOI · Paper page
  35. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R: A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001, 33: 1968-1974. 10.1086/324081. · DOI · Paper page
  36. Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG: Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001, 52: 663-670. · doi:10.1046/j.0306-5251.2001.01482.x
  37. Schneider P, Schoone G, Schallig H, Verhage D, Telgt D, Eling W, Sauerwein R: Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol. 2004, 137: 35-41. 10.1016/j.molbiopara.2004.03.018. · DOI
  38. Sinden RE, Carter R, Drakeley C, Leroy D: The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies. Malar J. 2012, 11: 70-10.1186/1475-2875-11-70. · DOI
  39. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, Bousema T, Drakeley CJ, Ghani AC: The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One. 2011, 6: e20179-10.1371/journal.pone.0020179. · DOI · Paper page
  40. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A: Malaria eradication on islands. Lancet. 2000, 356: 1560-1564. 10.1016/S0140-6736(00)03127-5. · DOI · Paper page
  41. Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wust K, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer H, Kouyaté B, Müller O: Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health. 2005, 10: 32-38. 10.1111/j.1365-3156.2004.01356.x. · DOI
  42. Meissner PE, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Tapsoba T, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer H, Kouyaté B, Müller O: Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J. 2005, 4: 45-10.1186/1475-2875-4-45. · DOI
  43. Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U, Mockenhaupt FP, Burhenne J, Mikus G, Walter-Sack I, Schirmer RH, Sié A, Meissner P, Müller O: Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health. 2010, 15: 713-717. 10.1111/j.1365-3156.2010.02526.x. · doi:10.1111/j.1365-3156.2010.02526.x
  44. Coulibaly B, Zoungrana A, Mockenhaupt FP, Schirmer RH, Klose C, Mansmann U, Meissner PE, Muller O: Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One. 2009, 4: e5318-10.1371/journal.pone.0005318. · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Eziefula, A. C., Gosling, R., Hwang, J., Hsiang, M. S., Bousema, T., von Seidlein, L., & Drakeley, C.
Venue
Malaria Journal
Published
2012-10-30
Volume
11
Issue
1
ISSN
1475-2875
Cited by
46
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.